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TO THE EDITOR
B-cell-attracting chemokine 1/CXCL13
and secondary lymphoid tissue chemo-
kine/CCL21 are constitutively expressed
within secondary lymphoid organs, reg-
ulating homing of lymphocyte and
dendritic cells to these organs (Nagira
et al., 1997, Gunn et al., 1998a; Legler
et al., 1998; Yoshida et al., 1998).
CXCL13 is a ligand for CXCR5 (Dobner
et al., 1992), which is mainly expressed
on B cells (Forster et al., 1994). CXCL13
is expressed by follicular dendritic cells
and other stromal cells located in the B-
cell areas of secondary lymphoid organs
(Gunn et al., 1998a; Ansel et al., 2000).
CCL21 is a ligand for CCR7 (Burgstahler
et al., 1995), which is highly expressed
on naı¨ve T cells and mature dendritic
cells (Sozzani et al., 1998; Yanagihara
et al., 1998; Saeki et al., 1999). CCL21 is
constitutively expressed by stromal cells
within the T-cell zones of secondary
lymphoid organs, endothelial cells of
high endothelial venules (HEVs), and
lymphatic vessels (Gunn et al., 1998b;
Nagira et al., 1998). Recently, several
researchers have recognized that
CXCL13 and CCL21 are also involved
in some human diseases. CXCL13 and
CCL21 expression was shown in lym-
phoid follicle-like structures in salivary
glands of Sjo¨gren syndrome and in-
flamed synovial specimens of rheuma-
toid arthritis (Shi et al., 2001; Manzo
et al., 2005; Barone et al., 2005).
Expression of CXCL13 was also shown
in lymphoproliferative disorders such as
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Figure 1. Ectopic follicular structures of the skin are positive for CXCL13 and CD21.
Immunohistochemistry for formalin-fixed paraffin-embedded sections was performed as described
previously (Barone et al., 2005). Immunohistochemical staining for CXCL13 (AF801, R&D Systems,
Abingdon, UK) of (a) reactive lymph nodes, (b) Kimura’s disease, (c) primary cutaneous follicle center
lymphoma, (d) primary cutaneous diffuse large B-cell lymphoma, and (e) cutaneous T-cell lymphoma.
Positive staining for CD21 (1F8 Dako, Cambridge, UK) in follicular structures of (f) Kimura’s disease.
Bar¼500 mm.
Abbreviation: HEV, high endothelial venule
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gastric mucosa-associated lymphoid tis-
sue lymphoma and central nervous
system lymphoma (Mazzucchelli et al.,
1999; Smith et al., 2003). Here, we
analyzed the relationship between
CXCL13 and CCL21 expression and
ectopic lymphoid structures in cuta-
neous lymphoproliferative disorders.
Skin and lymph node specimens were
obtained from the patients with Kimura’s
disease (five cases), pseudolymphoma
(six cases), primary cutaneous diffuse
large B-cell lymphoma (five cases), pri-
mary cutaneous marginal zone B-cell
lymphoma (two cases), primary cuta-
neous follicle center lymphoma (four
cases), cutaneous T-cell lymphoma
(seven cases), lichen planus (five cases),
and reactive lymphadenopathy (two
cases) over a period from 1985–2006 in
our department. All cases of cutaneous
lymphoma were diagnosed by the criteria
of World Health Organization-European
Organization for Research and Treatment
of Cancer (WHO-EORTC) classification
(Willemze et al., 2005). The medical
ethical committee of the University of
Tokyo approved all described studies and
the study was conducted according to the
Declaration of Helsinki Principles. Infor-
med consent was obtained to use tissue
specimens from patients and controls.
We first investigated the relationship
between CXCL13 expression and folli-
cular formation in the skin. There was
strong expression of CXCL13 within
follicular structures of Kimura’s disease
(Figure 1b) and pseudolymphoma with
prominent follicular formation similar
to reactive lymph nodes (Figure 1a). In
primary cutaneous marginal zone B-
cell lymphoma and primary cutaneous
follicle center lymphoma, CXCL13þ
cells were observed, but their localiza-
tion was not so distinct (Figure 1c).
CXCL13þ cells were very sparse or
almost negative in primary cutaneous
diffuse large B-cell lymphoma (Figure
1d). No CXCL13þ cells were detected
in cutaneous T-cell lymphoma (Figure
1e), lichen planus, and some cases of
pseudolymphoma in which follicular
formation was inconspicuous. As a
source of CXCL13, CD21þ follicular
dendritic cells were detected in lym-
phoid follicles of reactive lymph nodes
and skin specimens with prominent
follicular formation such as Kimura’s
disease (Figure 1f). CD20þ B cells
were located in these lymphoid follicles
as expected (data not shown). These
results suggested that CXCL13 ex-
pressed by follicular dendritic cells
induces chemotaxis of B cells, playing
important roles in lymphoid follicular
formation in the skin.
Expression of CXCL13 in cutaneous
lymphoid follicles is consistent with
recent reports suggesting that this che-
mokine may be involved in the patho-
genesis of several lymphocyte-
mediated diseases such as mucosa-
associated lymphoid tissue lymphoma
(Mazzucchelli et al., 1999). It was
indicated that the degree of expression
of CXCL13 was related to size and the
degree of follicular aggregates (Shi
et al., 2001). In our study, cases with
clear follicular structures showed folli-
cular localization of large numbers of
CXCL13þ cells. By contrast, cases
with moderate follicular structures
showed smaller numbers of CXCL13þ
cells. These results indicate that expres-
sion of CXCL13 is associated with
follicular formation in the skin.
We next investigated CCL21 expres-
sion because CCL21 is also critical for
lymphoid tissue organization. We ob-
served two types of CCL21þ dermal
vessels. One type had wide cavities
and flat one layer of endothelial
cells, which were also positively
stained with D2-40 (Figure 2a and b).
These vessels were observed in all
specimens and were regarded as lym-
phatic vessels. The other type had
smaller cavities with cuboidal endothe-
lial cells whose nuclei were large and
prominent, which were also positively
stained with peripheral lymph node
addressin (PNAd) (Figure 2c and d), a
good marker for HEVs (Michie et al.,
1993). These vessels were localized
to perifollicular area in reactive lymph
nodes, 4/5 of Kimura’s disease, and
pseudolymphoma with prominent folli-
cular formation. Closer examination
revealed that CCL21 staining was ob-
served on the outside of PNAdþ
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Figure 2. CCL21 is positive in D2-40þ lymphatics and on the outer side of PNAdþ HEV-like vessels.
Double staining for CCL21 (brown; AF366 R&D Systems, Abingdon, UK) and D2-40 (red; Nichirei,
Tokyo, Japan) of (a and b) Kimura’s disease. (b) Higher magnification of double-positive vessels with large
cavities and flat endothelial cells. Double staining for CCL21 (brown) and PNAd (red; MECA-79,
PharMingen, Oxford, UK) of (c and d) Kimura’s disease. (d) Higher magnification of double-positive
vessels with cubic endothelial cells. Immunohistochemical staining for (e) CD45RA (4KB5 Dako,
Cambridge, UK) and (f) CD45RO (UCHL1 Dako, Cambridge, UK) of Kimura’s disease. Bar¼100 mm.
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vessels. In 4/7 of cutaneous T-cell
lymphoma, PNAdþ HEV-like vessels
were distributed sparsely in the dermis,
but they were negative for CCL21.
PNAdþ HEV-like vessels were not
detected in lichen planus, and some
cases of pseudolymphoma in which
follicular formation was inconspicuous.
With regard to T-cell sub-popula-
tions (CD45RAþ naı¨ve T cells and
CD45ROþ memory T cells), CD45RAþ
cells were mainly located around
lymphoid follicles in reactive lymph
nodes, Kimura’s disease (Figure 2e), and
pseudolymphoma with prominent folli-
cular formation. The number of
CD45ROþ cells was extremely small
(Figure 2f). By contrast, most T cells
infiltrating in cutaneous T-cell lymphoma
and lichen planus were CD45RA and
CD45ROþ (data not shown). These
results suggested that CCL21 expressed
on PNAdþ HEV-like vessels induces
chemotaxis of CD45RAþ naive T cells,
playing important roles in lymphoid
follicular formation in the skin.
In all cases, some dermal vessels
were positively stained with CCL21,
which is natural considering that
CCL21 is known to be expressed by
endothelial cells of afferent lymphatic
vessels (Gunn et al., 1998b). Endothe-
lial cells of some vessels positively
stained with CCL21, however, were
cuboidal and had large and prominent
nuclei, which is characteristic of HEV
(Figure 2c and 2d). These double-
positive vessels were detected only in
cases showing follicular structures. It
suggests that dermal HEV-like vessels
expressing CCL21 is responsible for
formation of ectopic follicular struc-
tures in the skin.
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